Target intelligence / Profile preview

Excitatory amino acid transporter 2 (EAAT2)

Target
EAAT2
Molecular classification
Transporter, Solute carrier family
01

Overview

Excitatory amino acid transporter 2 (EAAT2), encoded by the SLC1A2 gene, is the primary protein responsible for the clearance of glutamate from the synaptic cleft in the mammalian central nervous system (UniProt: P43004). Predominantly expressed on the surface of astrocytes, it accounts for over 90% of all glutamate uptake, a process essential for terminating excitatory signals and preventing the toxic accumulation of glutamate. When EAAT2 function is compromised, excessive extracellular glutamate leads to overactivation of glutamate receptors, causing neuronal damage and death through a process known as excitotoxicity. This mechanism is a central feature in the pathophysiology of various neurological diseases, most notably amyotrophic lateral sclerosis (ALS), where a significant loss of EAAT2 protein is observed in the motor cortex and spinal cord.

Therapeutic development for EAAT2 focuses on small molecules that can either induce the expression of the transporter or enhance its kinetic activity. For instance, the antibiotic ceftriaxone was identified as a potent transcriptional inducer of EAAT2, although it failed to meet primary endpoints in clinical trials for ALS (, 25135316). Other compounds, such as LDN-212320, act as positive allosteric modulators to increase glutamate uptake and have shown promise in preclinical models of epilepsy and neurodegeneration. Despite the challenges in achieving brain permeability and target selectivity, EAAT2 remains a high-priority target for drug discovery aimed at restoring glutamate homeostasis in the diseased brain.

Other names
Solute carrier family 1 member 2SLC1A2Glutamate transporter 1GLT-1GLT1
02

Mechanism of action

Transcriptional upregulation of transporter expression or positive allosteric modulation to increase glutamate uptake capacity.

03

Biological functions

Glutamate homeostasisNeurotransmission terminationPrevention of excitotoxicitySynaptic plasticity
04

Disease associations

Amyotrophic lateral sclerosisAlzheimer's diseaseEpilepsyStrokeSchizophreniaNeurodegenerative disease
05

Safety considerations

Risk of disrupting normal excitatory signalingPotential for seizures if inhibitedOff-target effects of transcriptional activators
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Cerebrospinal fluid glutamate concentrationEAAT2 protein expression levelsPlatelet EAAT2 levels

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Excitatory amino acid transporter 2 (EAAT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Excitatory amino acid transporter 2 (EAAT2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call